Elmind Capital LP Acquires New Holdings in CytomX Therapeutics, Inc. $CTMX

Elmind Capital LP purchased a new position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 700,000 shares of the biotechnology company’s stock, valued at approximately $2,982,000. CytomX Therapeutics accounts for about 0.9% of Elmind Capital LP’s investment portfolio, making the stock its 25th largest holding. Elmind Capital LP owned about 0.41% of CytomX Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Orbimed Advisors LLC purchased a new stake in CytomX Therapeutics during the second quarter worth about $19,208,000. Commodore Capital LP purchased a new stake in CytomX Therapeutics during the second quarter worth about $17,462,000. Perceptive Advisors LLC purchased a new stake in CytomX Therapeutics during the second quarter worth about $15,876,000. State Street Corp increased its stake in CytomX Therapeutics by 697.1% during the fourth quarter. State Street Corp now owns 5,140,931 shares of the biotechnology company’s stock worth $21,900,000 after purchasing an additional 4,495,949 shares during the period. Finally, Baker BROS. Advisors LP increased its stake in CytomX Therapeutics by 22.0% during the third quarter. Baker BROS. Advisors LP now owns 4,250,826 shares of the biotechnology company’s stock worth $13,560,000 after purchasing an additional 766,600 shares during the period. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Wall Street Zen upgraded shares of CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Barclays boosted their price target on shares of CytomX Therapeutics from $10.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday, March 19th. JPMorgan Chase & Co. upgraded shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $7.00 to $12.00 in a research note on Monday, March 16th. HC Wainwright cut their price target on shares of CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Finally, Guggenheim boosted their price target on shares of CytomX Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $12.10.

CytomX Therapeutics Stock Performance

Shares of CytomX Therapeutics stock opened at $2.96 on Thursday. CytomX Therapeutics, Inc. has a one year low of $1.72 and a one year high of $8.21. The company has a market cap of $503.76 million, a PE ratio of -7.22 and a beta of 2.08. The business has a 50-day simple moving average of $3.84 and a 200-day simple moving average of $4.46.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. CytomX Therapeutics had a negative return on equity of 36.61% and a negative net margin of 166.40%.The business had revenue of $10.26 million during the quarter, compared to the consensus estimate of $4.68 million. On average, sell-side analysts predict that CytomX Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.